HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy

This article was originally published in The Tan Sheet

Executive Summary

Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team

You may also be interested in...

Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals

Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)

Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales

Perrigo's planned introduction of two generic loratadine formulations in early 2004 is expected to improve the firm's lackluster cough/cold sales in the second half of its fiscal year

Perrigo To Enter Generic Rx Drug Market With OTC Experience In Mind

Perrigo plans to complement its OTC pharmaceutical drug business with a foray into generic prescription drugs next year

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts